Celldex Therapeutics, Inc. (CLDX) Receives Average Rating of “Hold” from Analysts

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have earned a consensus recommendation of “Hold” from the nine brokerages that are covering the stock, Marketbeat reports. Three analysts have rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $8.13.

Several research analysts have weighed in on the company. HC Wainwright set a $10.00 target price on Celldex Therapeutics and gave the stock a “buy” rating in a report on Friday. BidaskClub lowered Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a report on Thursday, January 11th. Finally, WBB Securities reiterated a “buy” rating and set a $10.00 target price on shares of Celldex Therapeutics in a report on Wednesday, December 6th.

Celldex Therapeutics (NASDAQ:CLDX) traded down $0.07 during mid-day trading on Friday, reaching $2.38. The company’s stock had a trading volume of 1,801,655 shares, compared to its average volume of 1,180,000. The company has a market capitalization of $314.40, a price-to-earnings ratio of -2.36 and a beta of 2.57. Celldex Therapeutics has a 52-week low of $2.20 and a 52-week high of $3.94.

A number of hedge funds have recently bought and sold shares of CLDX. Cubist Systematic Strategies LLC bought a new position in Celldex Therapeutics during the third quarter worth about $101,000. OxFORD Asset Management LLP bought a new position in Celldex Therapeutics during the third quarter worth about $122,000. Teacher Retirement System of Texas lifted its holdings in shares of Celldex Therapeutics by 325.0% in the fourth quarter. Teacher Retirement System of Texas now owns 43,253 shares of the biopharmaceutical company’s stock valued at $123,000 after purchasing an additional 33,077 shares in the last quarter. Voya Investment Management LLC lifted its holdings in shares of Celldex Therapeutics by 17.4% in the second quarter. Voya Investment Management LLC now owns 50,535 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 7,499 shares in the last quarter. Finally, BlueCrest Capital Management Ltd bought a new stake in shares of Celldex Therapeutics in the second quarter valued at about $158,000. Hedge funds and other institutional investors own 52.38% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.com-unik.info/2018/02/10/celldex-therapeutics-inc-cldx-receives-average-rating-of-hold-from-analysts.html.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit